Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)		12 Months Ended
	Apr. 26, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Oct. 02, 2019	Jul. 02, 2019	Feb. 08, 2019
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary		$ 2,678,000	$ 0	$ 0
Specialty Pharma
Business Acquisition, Contingent Consideration [Line Items]
Equity method investments, fair value		0
Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Aggregate cash proceeds of intangible assets and remaining inventory	$ 250,000
Internal Revenue Service (IRS) | Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount of filed claims likely to be denied					$ 9,302,000	$ 50,695,000
DIP Credit Agreement | Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
Payments for debtor in possession financing		407,000
Gain (loss) on deconsolidation of subsidiary		$ 407,000
DIP Credit Agreement | Debtor in Possession Credit and Security Facility | Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
DIP financing, amount arranged							$ 2,700,000